busulfan has been researched along with Lung Diseases, Interstitial in 9 studies
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 6.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion with IgM monoclonal antibody T10B9 plus complement and posttransplant cyclosporine-A." | 3.69 | Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. ( Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R, 1995) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 2.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| "We treated 51 patients with various hematological malignancies involving the bone marrow with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) followed by reinfusion of autologous peripheral blood stem cells." | 2.68 | Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. ( Agaliotis, DP; Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Janssen, WE; Perkins, JB; Zorksy, PE, 1996) |
| " Etoposide at a dose of 60-65 mg/kg in combination with TBI and cyclophosphamide was associated with a significantly increased incidence of life threatening or fatal toxicities compared with a combination using a dose of 25-50 mg/kg (15 of 24 vs." | 1.29 | Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. ( Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Scobioala, S | 1 |
| Eich, HT | 1 |
| OLINER, H | 1 |
| SCHWARTZ, R | 1 |
| RUBIO, F | 1 |
| DAMESHEK, W | 1 |
| Rodriguez, R | 1 |
| Nademanee, A | 1 |
| Ruel, N | 1 |
| Smith, E | 1 |
| Krishnan, A | 1 |
| Popplewell, L | 1 |
| Zain, J | 1 |
| Patane, K | 1 |
| Kogut, N | 1 |
| Nakamura, R | 1 |
| Sarkodee-Adoo, C | 1 |
| Forman, SJ | 1 |
| Casper, J | 1 |
| Camitta, B | 1 |
| Truitt, R | 1 |
| Baxter-Lowe, LA | 1 |
| Bunin, N | 1 |
| Lawton, C | 1 |
| Murray, K | 1 |
| Hunter, J | 1 |
| Pietryga, D | 1 |
| Garbrecht, F | 1 |
| Klingemann, HG | 1 |
| Shepherd, JD | 1 |
| Reece, DE | 1 |
| Barnett, MJ | 1 |
| Nantel, SH | 1 |
| Sutherland, HJ | 1 |
| Spinelli, JJ | 1 |
| Phillips, GL | 1 |
| Spitzer, TR | 1 |
| Peters, C | 1 |
| Ortlieb, M | 1 |
| Tefft, MC | 1 |
| Torrisi, J | 1 |
| Cahill, R | 1 |
| Gadner, H | 1 |
| Urban, C | 1 |
| Deeg, HJ | 1 |
| Ballester, OF | 1 |
| Agaliotis, DP | 1 |
| Hiemenz, JW | 1 |
| Janssen, WE | 1 |
| Fields, KK | 1 |
| Zorksy, PE | 1 |
| Goldstein, SC | 1 |
| Perkins, JB | 1 |
| Elfenbein, GJ | 1 |
| Ringdén, O | 1 |
| Remberger, M | 1 |
| Ruutu, T | 1 |
| Nikoskelainen, J | 1 |
| Volin, L | 1 |
| Vindeløv, L | 1 |
| Parkkali, T | 1 |
| Lenhoff, S | 1 |
| Sallerfors, B | 1 |
| Mellander, L | 1 |
| Ljungman, P | 1 |
| Jacobsen, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML[NCT00001144] | Phase 2 | 50 participants | Interventional | 1999-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for busulfan and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Thera | 2020 |
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1994 |
2 trials available for busulfan and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modalit | 1996 |
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Catara | 1999 |
5 other studies available for busulfan and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Interstitial pulmonary fibrosis following busulfan therapy.
Topics: Busulfan; Humans; Lung Diseases, Interstitial; Pulmonary Fibrosis | 1961 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Su | 2006 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycl | 1995 |
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1994 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-1997. A 60-year-old man with pulmonary infiltrates after a bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow Transplantation; Busulfan; Cryptogenic Organi | 1997 |